Mitomycin Accord (Mitomycin)

Mitomycin Accord is an antineoplastic antibiotic used in the management of malignant tumours that rely on DNA synthesis pathways.

• Bladder cancer: provides cytotoxic activity that can reduce tumour burden when administered intravesically.
• Gastric cancer: contributes to tumour regression as part of combination chemotherapy regimens.
• Pancreatic cancer: offers DNA cross‑linking effects that enhance overall response rates.
• Breast cancer: used in selected protocols for advanced disease to inhibit cell proliferation.
• Head and neck cancer: applied in combination therapy to improve local control.

• Mitomycin exerts its antineoplastic effect by undergoing enzymatic reduction within hypoxic tumour cells, forming a reactive intermediate that covalently cross‑links DNA strands. This cross‑linking blocks DNA replication and transcription, ultimately triggering apoptosis and cell death in rapidly dividing cancer cells.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset occurring during or after infusion.
• Myelosuppression: reduced white blood cells, red cells and platelets.
• Hematuria: blood in urine, especially after intravesical administration.
• Fatigue: generalized tiredness during treatment cycles.

Serious or Rare Side Effects

• Pulmonary fibrosis: progressive scarring of lung tissue.
• Severe infection: opportunistic infections due to immunosuppression.
• Renal toxicity: impaired kidney function, particularly with intravesical use.

Mitomycin requires careful monitoring and specific safety measures before, during and after administration.

• Renal function: assess creatinine clearance prior to intravesical dosing.
• Hepatic function: evaluate liver enzymes to adjust systemic exposure.
• Hematologic monitoring: perform regular CBC to detect myelosuppression.
• Pregnancy and lactation: avoid use; potential teratogenic risk is unknown.
• Concomitant nephrotoxic agents: avoid or adjust dosing when used together.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Mitomycin may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid)

• High‑dose cyclophosphamide: additive bone‑marrow suppression.
• Nephrotoxic antibiotics (e.g., aminoglycosides): increased risk of renal injury.
• Anticoagulants (warfarin, DOACs): heightened bleeding tendency.

Moderate Interactions (Monitor Closely)

• NSAIDs: may exacerbate renal dysfunction.
• CYP450 inducers (e.g., rifampin): could reduce mitomycin plasma levels.